Chimeric Therapeutics Ltd has released a press release.
Response to ASX Query Letter
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Additional complete responses in CHM CORE-NK Phase 1b trial
- Disease control and tumour shrinkage observed in CHM CDH17
- Appendix 4E and Annual Report
- CHM CDH17 Clinical Trial Update
- Chimeric receives $2.5 M advance on FY25 R&D tax incentive
Later from Chimeric Therapeutics
- Pause in Trading
- CHM CORE NK Combination Phase 1b trial update
- 75% disease control observed in CHM CDH17 trial
- Chimeric receives $4.5M R&D tax incentive
- CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics